Advanced search
Publication Cover
Journal of Chemotherapy Volume 30, 2018 - Issue 1
Submit an article Journal homepage
146
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms

Giovanni BrandiDepartment of Experimental, Diagnostic and Speciality Medicine, ‘L. & A. Seragnoli’ Institute of Hematology and Medical Oncology, Sant’Orsola-Malpighi Hospital, Bologna, Italy;Interdepartmental Center for Cancer Research (CIRC), Sant’Orsola-Malpighi Hospital, Bologna, ItalyCorrespondence[email protected]
,
Marco ParagonaDepartment of Experimental, Diagnostic and Speciality Medicine, ‘L. & A. Seragnoli’ Institute of Hematology and Medical Oncology, Sant’Orsola-Malpighi Hospital, Bologna, Italy
,
Davide CampanaInternal Medicine Unit, Medical and Surgical Sciences Department, Sant’Orsola-Malpighi Hospital, Bologna, Italy
,
Nicole BrighiDepartment of Experimental, Diagnostic and Speciality Medicine, ‘L. & A. Seragnoli’ Institute of Hematology and Medical Oncology, Sant’Orsola-Malpighi Hospital, Bologna, Italy
,
Arrigo BondiCytological and Pathological Anatomy Unit, Maggiore Hospital, Bologna, Italy
,
Maria Abbondanza PantaleoDepartment of Experimental, Diagnostic and Speciality Medicine, ‘L. & A. Seragnoli’ Institute of Hematology and Medical Oncology, Sant’Orsola-Malpighi Hospital, Bologna, Italy;Interdepartmental Center for Cancer Research (CIRC), Sant’Orsola-Malpighi Hospital, Bologna, Italy
,
Jody CorbelliDepartment of Experimental, Diagnostic and Speciality Medicine, ‘L. & A. Seragnoli’ Institute of Hematology and Medical Oncology, Sant’Orsola-Malpighi Hospital, Bologna, Italy
,
Maria Aurelia BarberaDepartment of Experimental, Diagnostic and Speciality Medicine, ‘L. & A. Seragnoli’ Institute of Hematology and Medical Oncology, Sant’Orsola-Malpighi Hospital, Bologna, Italy
&
Guido BiascoDepartment of Experimental, Diagnostic and Speciality Medicine, ‘L. & A. Seragnoli’ Institute of Hematology and Medical Oncology, Sant’Orsola-Malpighi Hospital, Bologna, Italy;Interdepartmental Center for Cancer Research (CIRC), Sant’Orsola-Malpighi Hospital, Bologna, Italy
 show all
Pages 53-58 | Published online: 22 Jun 2017

References

  • Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon, (France): IARC Press; 2010.
  • Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85.10.1159/000443167
  • Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.10.1159/000443171
  • Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–38.10.1159/000443170
  • Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68(2):227–32.10.1002/(ISSN)1097-0142
  • Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81(8):1351–5.10.1038/sj.bjc.6690325
  • Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92(5):1101–7.10.1002/(ISSN)1097-0142
  • Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40(4):313–8.10.1093/jjco/hyp173
  • Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685–90.10.1023/A:1008215730767
  • Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762–71.10.1200/JCO.2004.04.024
  • Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43(3):422–7.10.1136/gut.43.3.422
  • Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12(4):1083–92.10.1677/erc.1.01017
  • Bettini R, Boninsegna R, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19(5):903–8.10.1093/annonc/mdm552
  • Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8.10.1200/JCO.2011.40.4905
  • Yagamuchi T, Machida N, Kasuga A, Takahashi H, Sudo K, Nishina T, et al. Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. J Clin Oncol. 2012;30 (Suppl. 4):274.
  • Al-Ajam M, Seymour A, Mooty M, Leaf A. Ten years of disease-free survival between two diagnoses of small-cell lung cancer: a case report and a literature review. Med Oncol. 2005;22(1):89–98.10.1385/MO:22:1
  • Lewiński T, Zuławski M. Small cell lung cancer survival: 3 years as a minimum for predicting a favorable outcome. Lung Cancer. 2003;40(2):203–13.10.1016/S0169-5002(03)00025-4
  • Jacoulet P, Depierre A, Moro D, Rivière A, Milleron B, Quoix E, et al. Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d’Oncologie de Langue Française. Ann Oncol. 1997;8(10):1009–14.10.1023/A:1008287922285
  • Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years–an analysis of 1,714 consecutive patients. J Clin Oncol. 1995;13(5):1215–20.10.1200/JCO.1995.13.5.1215
  • Skarin AT. Analysis of long-term survivors with small-cell lung cancer. Chest. 1993;103(4):S440–4.10.1378/chest.103.4_Supplement.440S

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.